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Investigations over two decades have revised understanding of the prolactin hormone. Long thought to
be merely a lactogenic hormone, its list of functions has been extended to include: reproduction, islet
differentiation, adipocyte control and immune modulation. Prolactin functions by binding cell-surface
expressed prolactin receptor, initiating signaling cascades, primarily utilizing Janus kinase-signal
transducer and activator of transcription (JAK-STAT). Pathway disruption has been implicated in
tumorigenesis, reproductive abnormalities, and diabetes. Prolactin can also be secreted from extrap-
ituitary sources adding complexity to understanding of its physiological functions. This review aims to
describe how prolactin exerts its pathophysiological roles by endocrine and autocrine means.
 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The hormone prolactin has long been recognized for its role in
lactation. However, evidence has emerged of its more promiscuous
nature, with proposed functions as diverse as islet differentiation,
immune modulation, adipocyte control and reproduction (Fig. 1).
With such a variety of functions reputedly contributed to by pro-
lactin it is perhaps unsurprising that its receptor, the prolactin re-
ceptor (PRLR), is expressed on diverse tissues [1e6]. The PRLR is a
type-I cytokine receptor that signals predominantly via the JAK2-
STAT5 signaling pathway, but is capable of initiating other signal
cascades [7]. The structure and signaling pathways of prolactin and
its receptor have been the focus of several excellent reviews [7,8]
and therefore will not be the focus of this review. Instead, the
pathophysiological roles of prolactin will be discussed, taking into
consideration both its endocrine role, when produced by the pitu-
itary, and its autocrine role, when produced locally by tissues.Role of PRLR in lactation and reproduction
A role for prolactin in lactation has been established for decades,
yet new insights continue to emerge. Prolactin plays a crucial role in
two reproductive functions: mammary gland development during
late gestation and the early post-partum period, and formation of
the corpus luteum following blastocyst implantation [9,10].nc. This is an open access article uDuring pregnancy the mammary gland undergoes extensive
ductal side-branching and alveolar budding evolving to a milk-
secreting gland [11]. Prolactin contributes to both proliferation
and differentiation of mammary tissue [12]. Prlr/ mice do not
develop mammary gland terminal-end buds and are unable to
lactate, similarly to Jak2-conditional and Stat5a-conventional
knockout mice [13e17]. Impairment of mammary gland develop-
ment is not as severe in Stat5b-null mice, but milk protein pro-
duction is affected, demonstrating both STAT5 components are
necessary for lactation [18,19]. Furthermore, these studies suggest
that other PRLR-mediated signaling pathways, and PRLR-
independent pathways, are unable to fully compensate for the
JAK-STAT pathway in mammary gland function.
Both long and short forms of PRLR are required for milk protein
expression and lactation [20]. Initial studies of Prlrþ/ mice
demonstrated impaired mammary gland alveolar differentiation
and failure to lactate on ﬁrst pregnancy, but recovery on subsequent
pregnancies [15,16,21,22]. However, later investigations showed
this recovery may be mouse strain dependent as breeding onto a
pure C57BL/6 background could not rescue heterozygous lactation
in most animals [23]. Mammary gland developmental defects
observed in Prl/ and Prlr/ mice are largely mediated by loss of
the progesterone surge in early pregnancy [16,24]. Treatment of
mice with progesterone restores ductal side-branching defects [15].
The progesterone surge is produced by the corpus luteum, and is
necessary for decidualization of endometrial tissue [10]. PRLR
expression increases at decidualization [10,25] and prolactin stimu-
lates progesterone secretion andprogesterone receptor expression on
uterine epithelium, providing favorable conditions for implantationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Summary of the diverse functions of the PRLR. The PRLR is proposed to have a role in reproduction, islet differentiation, regulation of fat stores and immune responses. PRLR
is expressed on mammary gland cells, pancreatic b-cells, adipocytes and immune cells. Prolactin secreted by the pituitary gland has a number of physiological effects on these
tissues (black text). Prolactin can also be secreted by cells within these tissues, leading to autocrine effects. Impairments of these functions due to mutation of the receptor, or
changes in expression, may lead to pathological states (green text).
C.M. Gorvin / Journal of Clinical & Translational Endocrinology 2 (2015) 85e9186[8,26]. Prolactin reduces the frequency and amplitude of luteinizing
hormone pulses by direct actions on gonadotropin-releasing hor-
mone neurons, and indirectly via g-aminobutyric acid and kisspeptin
neurons [27]. Prlr/ femalemice are hyperprolactinemic and infertile
[16]. Egg development, ovulation and blastocyst implantation are
reduced in Prlr-null mice [16,21,24,26]. In addition, corpus luteal for-
mation is regressed in early pregnancy and progesterone production
reduced [26]. As in themammary gland, progesterone administration
is able to rescue these phenotypes in Prlr/ mice [28]. Full corpus
luteal formation requiresbothSTAT5aandSTAT5basdoubleknockout
mice are infertile, with no corpus luteum, while single knockouts
retain some fertility [18,19,29]. Autocrine prolactin produced by
uterine cells may also have a function in maintenance of the corpus
luteum following initial formation [10].
Hyperprolactinemic patients have variable reproductive abnor-
malities. 40% of hyperprolactinemic women have amenorrhea [27],
other patients have galactorrhea, infertility or hypogonadism [30].
The variability in reproductive abnormalities in humans is reﬂected
in the recently reported hyperprolactinemic family, which harbor a
heterozygous PRLR-H188R loss-of-function mutation [31]. The
three sisters reported in this study had a shared phenotype of oli-
gomenorrhea, with galactorrhea and infertility also reported [31].
This infertility was not accompanied by abnormal ovulation, and
luteal phase progesterone levels were normal [31]. Differences in
reproductive abnormalities in patients could stem from different
causes of hyperprolactinemia, utilization of different PRLR isoforms,
or in the case of this family, from the heterozygous nature of the
mutation. Discovery of further families with PRLR mutations could
yield further insights into these differences.Prolactin is less abundant in males than females, consistent with
the hormone’s primary role in lactation. However, male-speciﬁc
roles may exist. Hyperprolactinemic patients experience erectile
dysfunction (16%) and oligospermia (10%) [27]. Prl-null mice have
reduced ventral prostateweight compared towild-type littermates,
and mice overexpressing prolactin have prostate hyperplasia
[32,33]. Similarly, rats with chronic hyperprolactinemia have
prostate enlargement [34]. However, Prlr/ mice have normal
plasma testosterone levels and testicular weights [35] and despite a
reduced ability to produce a ﬁrst pregnancy in Prlr/ male mice,
subsequent matings were successful [36].
Role of PRLR in tumourigenesis
Elevated PRLR expression and high circulating levels of prolactin
have been associated with increased risk of tumor progression and
invasion [37e39]. Prospective studies demonstrate up to 95% of
female mammary tumors, and 60% of male breast carcinomas ex-
press prolactin and/or PRLR [40e42]. This association is replicated in
animal models including transgenic mice overexpressing prolactin
that develop mammary carcinoma [43,44]. In humans, a direct
correlation between single nucleotide polymorphisms (SNPs) in PRL
and/or PRLR and tumor incidence has been sought. Many of these
studies failed to identify associations [45e48], however two SNPs,
PRLR-I70V and I146L, demonstrate constitutive receptor activity,
with one correlating with the occurrence of benign breast disease in
a patient cohort [49]. However, these patients did not have elevated
serum prolactin, nor did they have differences in other clinical pa-
rameters investigated [49,50]. Furthermore, other studies in which
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with cancer prognosis, casting doubt on their importance in
neoplasia, not least because of their high prevalence in the normal
population [31,46,48]. Other non-coding SNPs in PRL or PRLR have
been associated with breast cancer, however their functional effects
are unknown [47,51]. Larger cohorts of cancer patients and a better
understanding of PRLR variants across normal populations are
required to better understand its role in pathogenesis.
The molecular mechanisms by which prolactin exerts mitogenic
actions are being explored, and it is likely multiple complex path-
ways are involved. This is complicated further by emerging hy-
potheses that prolactin may alter its signal transduction pathways
in breast carcinogenesis. Thus many breast tumors are character-
ized by reduced STAT5 despite high levels of PRLR expression
[52,53]. Often these tumor subtypes: exhibit high levels of mitogen-
activated protein kinase (MAPK) signal components including
activator protein-1 (AP-1) and pro-invasive matrix metal-
loproteinases (MMPs); are highly invasive; are associated with
resistance to chemotherapy and anti-estrogen treatments; and
have a poor prognosis [54]. The tumor microenvironment may be
responsible for favoring one signal pathway over another [55]. Stiff
collagen matrices are associated with invasive breast cancer [55]
and shift prolactin signaling proﬁles from STAT5-mediated path-
ways to focal-adhesion kinase and MAPK pathways, favoring pro-
liferation [55]. Furthermore, prolactin signals in high-density
matrices, increased MMP expression and favored a disorganized
structure allowing for cellular motility [55]. Blocking JAK2 had a
similar effect, elevating extracellular signal-regulated kinase 1/2
(ERK1/2) and transforming growth factor-b favoring epithelial-
mesenchymal-transition and tumor metastasis [56].
The tumor microenvironment potentially holds the key to
deciphering the complex interplay between PRLR and estrogen
receptor (ERa). Whilst expression of ERa or PRLR alone had no ef-
fect on tumor progression, co-expression of PRLR and ERa within a
non-compliant, stiff matrix is associated with increased invasive-
ness in tumor cell models and reduced responsiveness to estrogen
antagonists [57]. Furthermore, co-operativity between the two
pathways exists with each hormone inducing expression of the
reciprocal receptors in cellular studies [58e60].
Other molecular markers of breast cancer exist within the PRLR
pathway. PRLR turnover mediated by phosphorylation of S349 is
critical in preventing long-term stabilization of the receptor that
favors tumor progression [41]. Receptors resistant to degradation
had higher levels of MMP9 and exhibited invasive behaviors [41,61].
A novel protein partner of the PRLR, calcium-modulating cyclophilin
ligand (CAML), is highly expressed in breast cancer [62]. CAML acts
as a scaffold protein, prolonging PRLR interaction with signal
transduction components, and increasing proliferation [62]. Studies
have also revealed an intrinsic component of the PRLR pathwaymay
contribute to understanding of prolactin’s role in tumorigenesis. The
STAT5 proteins, STAT5a and STAT5b, though highly related, have
distinct expression patterns in breast tumors where nuclear STAT5a
is reduced, while STAT5b remains unchanged [63]. This low level of
STAT5a was associated with poor prognosis [63], indicating it could
act as a novel biomarker to predict tumor outcomes. This ﬁnding
may explain some of the conﬂicting reports regarding STAT5
expression in breast cancer, as commonly used antibodies often
cannot distinguish between STAT5a and STAT5b proteins [63].
Investigation of the neoplastic role of prolactin has been further
hampered by the indiscriminate study of global prolactin, without
consideration of prolactin produced by the mammary gland [64].
Autocrine prolactin production has been shown in human breast
tissue [65,66], and in mouse models (following hypophysectomy
[65], and in the transgenic NRL-PRL mouse model that enriches
prolactin within the mammary environment, while retainingnormal global prolactin levels) [59,67]. In NRL-PRL female mice
estrogen treatment, although not necessary for tumor develop-
ment, enhances prolactin-induced tumorigenesis [68]. However,
one study examining breast cancer tumors and cell-lines was un-
able to detect elevated prolactin [44], concluding that autocrine
prolactin may not be important in all patients.
The prolactin autocrine-paracrine loop may play a role in male
breast carcinoma [40] and other reproductive cancers including
cervical [69] and prostate cancer [34,40]. Evidence for this autocrine
role is provided by transgenic mice overexpressing Prl under a
prostate-speciﬁc promoter (Pb-PRL) that developed prostate hy-
perplasia in the absence of elevated serum androgen levels [70].
There is still much to be learned about the role of prolactin and its
receptor in tumorigenesis. It is likely further investigation of the tu-
mor microenvironment and the effects of autocrineeparacrine
signaling will yield new avenues of investigation. Further, a greater
understanding of the molecular signatures of breast tumors could
highlight new therapeutic targets, yielding fresh hope for drugs tar-
geting PRLR pathways that have thus far produced poor results [67].
Role of PRLR in islet proliferation
The PRLR is highly expressed at the pancreatic b-cell, and may
play a fundamental role in the b-cell expansion that occurs to meet
increased metabolic demands required during pregnancy [5,71].
Correlations between the rise in b-cell mass and themid-pregnancy
lactogenic surge led to the hypothesis that prolactin and placental
lactogen drives this b-cell differentiation [5,71]. In support of this
hypothesis cellular studies show the lactogenic hormones increase
PRLR expression on b-cells, induce b-cell replication and increase
glucose-stimulated insulin secretion (GSIS) [5,72] In vivo studies
provide further evidence. Prlr/ mice had reduced b-cell mass,
reduced islet density, impaired glucose tolerance, reduced insulin
secretion, and islets contain 20e35% less insulin [5]. Heterozygous
mice similarly had impaired glucose tolerance, which was affected
by maternal genotype, with more pronounced impairments in
those with heterozygous mothers [5]. This is reminiscent of human
gestational diabetes in which it has been observed that prenatal
exposure to gestational diabetes increases its risk in the next gen-
eration [73].
In vitro and in vivo studies have provided a wealth of data on
prolactin’s effect on pancreatic islets allowing rudimentary pathway
insights. Prolactin largely regulates its functions on the pancreatic b-
cell via the JAK2-STAT5 pathway [74]. Cells infected with Ad-
shSTAT5b that silences STAT5b, displayed reduced insulin signaling
[75]. Furthermore, mice injected with Ad-shSTAT5b had reduced
glucose tolerance, glucose clearance and insulin signaling in the liver
[75]. Mice in which pancreatic b-cell Stat5a/b has been deleted
exhibit no discernible defects in b-cell development, but aged and
pregnant mice are mildly glucose intolerant [76]. This phenotype
was milder than that observed in Prlr-null mice indicating STAT5
alone is not responsible for all prolactin-mediated effects on b-cells.
The activated PRLR acts as a hub to nucleate proteins from
diverse signaling pathways. The insulin-related substrate proteins
(IRS1-3) are one such protein family that act as signal adapters
allowing recruitment of Akt and phosphoinositide-3 kinase (PI3K),
that activate further signal cascades (e.g. MAPK) and gene tran-
scription. Prolactin induces phosphorylation of all three IRS proteins,
most likely via JAK2 [77]. Anti-sense PRLR blocks this prolactin-
induced increase in IRS1/2, Akt and ERK1/2 phosphorylation [78].
Downstream targets of these prolactin-induced pathways
include glucokinase [79] and cell-cycle proteins (e.g. cyclin-D2)
[71,80] and transcription factors (e.g. forkhead-box protein D3
(FOXD3)) [81]. Glucokinase regulates the rate-limiting step
in glucose metabolism [79]. Its expression is increased in
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mechanism is STAT5-dependent and leads to increased insulin
secretion [79]. PRLR-siRNA treatment reduces cyclin-D2 expression
in INS-1 cells [71,80] and cyclin-D2 knockout mice are glucose-
intolerant [82]. However, Prlrþ/ mice had normal CCND2 expres-
sion levels [83]. Pancreas-speciﬁc deletion of FoxD3 leads to
gestational diabetes in mice characterized by impaired glucose
tolerance, reduced b-cell mass and reduced b-cell proliferation [81].
The wild-type offspring of Prlrþ/ mice have reduced FoxD3 and
decreased Akt phosphorylation [73], indicating FOXD3 is a major
driver of Akt-mediated b-cell proliferation [73].
PRLR may mediate its effect on islets in part by regulating the tu-
mor suppressor protein menin. In the normal state, menin regulates
expression of the cyclin-dependent kinase p27 and p18, whose
function is to inhibit islet proliferation [84]. However, in the pregnant
state, menin, p27 and p18 are reduced, which coincides with the
increased proliferation observed in pancreatic b-cells [83]. Prlrþ/
mice also have elevated p18 and fail to increase IRS2 and Akt
expression [83]. These ﬁndings, when considered in light of previous
ﬁndings that prolactin increases BCL6-mediated repression of MEN1
transcriptionviaSTAT5activation [84], indicate that the reducedb-cell
mass observed in Prlrþ/mice may be mediated by prolactin’s action
on menin, via Akt and JAK-STAT pathways within pancreatic b-cells.
Other regulators of the prolactin-induced effects during preg-
nancy have emerged recently, though their precise roles remain
controversial. These include the enzyme tryptophan hydroxylase
(Tph1) that regulates the rate-limiting step in serotonin synthesis
that was reported to be increased during pregnancy [85]. Mice fed a
low-tryptophan diet had mild gestational glucose intolerance [85].
Furthermore, prolactin treatment was shown to increase Tph1
expression and serotonin synthesis during pregnancy [85], whilst
PRLR knockdown in insulinoma cells reduced Tph1 expression [71].
This led to the proposed model inwhich lactogenic hormones drive
the expression of Tph1 and its receptor on target cells leading to
Gaq-mediated activation of b-cell proliferation during pregnancy,
followed by Gai-mediated inhibition of b-cell proliferation in the
post-partum period [85]. Although, Schraenen et al. [86], were able
to demonstrate a similar increase in Tph1 induction by PRLR-JAK2-
STAT5 in a subset of islets, they observed no differences in b-cell
proliferation in Tph1-null mice compared to control mice [86]. Such
discrepancies may lie in the mouse strains used to study these ef-
fects as proposed recently by Goyvaerts et al. [87]. Alternatively, the
serotonin-induced effects may be mediated via a different mecha-
nism, such as the b-cell expressed serotonin-gated cation channel
that has been shown to depolarize the b-cell membrane, thus
lowering the threshold for glucose-stimulated insulin secretion
required during pregnancy [88]. Such ﬁndings have highlighted the
requirement for further investigation of the function of serotonin in
human islets, and the role PRLR plays.
In spite of growing evidence that prolactin plays a critical role in
regulating b-cell changes observed in pregnancy, a convincing role
in man has yet to be identiﬁed. Studies of chronic hyper-
prolactinemia demonstrate patients have postprandial hyper-
insulinaemia and an exaggerated insulin secretory response to
glucose [89]. Furthermore, signiﬁcant associations between two
PRLR SNPs and gestational diabetes mellitus have been shown [90].
However, other studies could not demonstrate similar effects,
possibly due to the complex cross-talk between PRLR and insulin
receptor. Further research is required to determine the role, if any,
that prolactin plays in human pancreatic adaptation to pregnancy.
Role of PRLR in adipose tissue
In a situation analogous to that of the pancreatic islet, the adi-
pocytes must undergo extensive changes during pregnancy andlactation, comprising neuronal changes that permit increased food
intake, and fat store redistribution to satisfy energy demands [91].
During these periods fat store distribution shifts from abdominal
tissues to mammary glands [91]. Coincident with this fat redistri-
bution is the lactogenic surge at mid-to-late pregnancy, implicating
a role for prolactin in this process. Prlr/mice have reducedweight
gain after 16 weeks which is more obvious in females [92].
Consequently abdominal fat stores are reduced and fasting plasma
levels of the adipocyte hormone leptin are reduced in Prlr/ female
mice [92].
The role of prolactin in adipocyte differentiation in brown adi-
pose tissue (BAT) has been investigated [93]. BATmediates adaptive
thermogenesis, a process required for thermoregulation in neo-
nates. The protein UCP1 plays a critical role in this process by
shifting proton gradients generated at the inner mitochondrial
membrane from energy production to generate heat [94]. BAT mass
in neonate PRLR-null mice was signiﬁcantly reduced compared to
wild-type littermates, and brown adipocytes had decreased tri-
glyceride content [93]. Furthermore, these mice were more sensi-
tive to a cold challenge, and had reduced expression of uncoupling
protein-1 (UCP1), known to be involved in the thermogenesis
process, as well as genes involved in adipocyte differentiation (e.g.
peroxisome proliferator-activated receptor-g (PPARg)) [93]. Prlr/
neonates had smaller mitochondria in BAT. PRLR overexpression
rescued BAT differentiation in immortalized preadipocytes and
restored PRLR, UCP1 and PPARg protein expression illustrating the
critical role for PRLR in regulation of BAT differentiation. Further-
more, the authors demonstrated that IGF2 maymediate the growth
of adipocytes downstream of PRLR-STAT5 [93].
Modulation of food intake is partially controlled by the hormone
leptin whose receptor shares signaling pathways with PRLR. During
lactation, plasma leptin levels reduce by 40% [92]. Furthermore, rats
and mice have gestational leptin-resistance attributed to the lacto-
genic surge that occurs at this period [95]. The prolactin receptor
and leptin receptor share expression sites within the hypothalamus
and brainstem, thus crosstalk may exist between the receptors [96].
It has been suggested that PRLR activation induces increased
expression of suppressor-of-cytokine signaling (SOCS) proteins
which directly inhibit STAT3-mediated pathways downstreamof the
leptin receptor [96]. However, other studies suggest no interaction
between PRLR and the leptin receptor, as demonstrated by normal
responses exhibited by the Prlr/ mice exposed to a leptin antag-
onist [91]. Such discrepancies may have arisen because prolactin-
mediated effects require insulin coexpression [25,28].
In humans, sustained hyperprolactinemia caused by antipsy-
chotic drugs or prolactinoma is associated with weight gain and
insulin resistance [97]. This can be corrected by administration of
dopamine agonists such as bromocryptine [98]. Furthermore, two
SNPs located close to the PRL gene have been associated with
increased risk of obesity [99,100]. Examination of larger cohorts
with detailed phenotyping may provide fresh insight into PRLR’s
role in adipocytes.
Role of PRLR in immune responses
PRLR is expressed on all leukocytes of the immune system, and
highly expressed in the spleen and thymus [101]. Although
numerous in vitro studies have demonstrated prolactin can activate
immune system cells, this remains controversial, with evidence
indicating these ﬁndings may have no relevance in physiological
settings, not least because mouse models fail to replicate these
responses.
Studies demonstrate that prolactin enhances T-cell activation by
several means including: 1) activation of the earliest known T-cell
surface antigen, CD69, that is necessary for prolonged T-cell
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a-chain of the interleukin (Il)-2-receptor, that regulates prolifera-
tion and expansion of T-cell subsets [103]; 3) phosphorylation and
activation of the T-cell receptor component CD3, and second
messenger kinases Fyn and ZAP70 [64,104,105]; 4) enhanced
expression of CD40, CD80 and CD86 co-stimulatory molecules on
antigen presenting cells [106]; 5) induction of cytokines involved in
enhancing T-cell responses including Il-1, Il-12 Il-16 and interferon-
g [106,107]; and 6) sensitivity of immune responses to dopamine
agonists [106]. It is largely accepted that prolactin is unable to
initiate these responses in isolation, and more likely acts as an
adjuvant to existing immune responses, evidence of which is pro-
vided by enhanced activation of T-cell pathways in response to
concanavalin-A, lipopolysaccharide and phytohaemaglutinin (PHA)
stimuli [107e109].
Autoimmune states provide amodel to investigate prolactin’s role
in immunity. Multiple sclerosis (MS) is one such state, which is more
prevalent in females, indicating a possible hormone-driven effect.
Pregnant MS patients have increased relapse rates within the ﬁrst
three months post-partum, correlating with increased prolactin
levels [110]. Similarly in systemic lupus erythematosus (SLE),
elevated prolactin levels in patients correlate with disease severity
[110] and treatment with bromocryptine relieved symptoms [106].
However, SLE mouse models were unable to demonstrate an
enhancement of the condition in the presence of prolactin [110].
The controversies in this ﬁeld not only lie in these autoimmune
discrepancies. Much of the evidence for prolactin-mediated im-
mune responses are derived from in vitro studies using peripheral
blood mononuclear cells (PMBCs) or immortalized cells such as
Jurkat T-cells, which may not reﬂect the physiological state. In vivo
studies using Prl/ and Prlr/ mouse models have cast doubt on
prolactin-mediated immune modulatory functions. Prl/ mice
have comparable levels of CD4þ and CD8þ cells to wild-type lit-
termates [111]. Furthermore, PHA-stimulated T-cell and B-cell re-
sponses were only impaired in Prl/mice following thermal stress
[108], indicating PRL may not have a role in physiological states.
Prlr/ mice have no differences in either pro- or pre-B-cells,
mature circulating B-cells, early T-cell precursors, immunoglob-
ulin subclasses or NK-cells compared towild-type littermates [112].
In addition, combination treatments of PRL and concanavalin-A or
Listeria monocytogenes were unable to enhance immune responses
above that seen with pathogen alone [112].
Finally, studies of immune responses in affected members of the
hyperprolactinemic family with the PRLR-H188R mutation indi-
cated no changes in immune cell subsets [31]. Furthermore, pro-
lactin did not enhance T-cell responses to PHA in PMBCs isolated
from affected family members [31]. These studies indicate that the
role of prolactin in immune responses may be more complicated
than originally proposed, with the possibility that prolactin re-
sponses are mediated by another receptor.
Summary
Research within the last two decades has identiﬁed new and
unexpected roles for prolactin and its receptor, governed by mul-
tiple signaling pathways. Potential pathogenic roles in infertility,
cancer, diabetes and obesity raise the possibility that PRLR and/or
its downstream pathways will likely lead to novel therapies in these
vital and highly prevalent disease states.
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